RT Journal Article
SR Electronic
T1 Detection and clearance of type-specific and phylogenetically related genital human papillomavirus infections in young women in new heterosexual relationships
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.24.23286387
DO 10.1101/2023.02.24.23286387
A1 Arthur, Andrew W.
A1 El-Zein, Mariam
A1 Burchell, Ann N.
A1 Tellier, Pierre-Paul
A1 Coutlée, Francois
A1 Franco, Eduardo L.
YR 2023
UL http://medrxiv.org/content/early/2023/02/26/2023.02.24.23286387.abstract
AB Background Understanding the natural history of human papillomavirus (HPV) infections is essential to effective cervical cancer prevention planning. We examined these outcomes in-depth among young women.Methods The HPV Infection and Transmission among Couples through Heterosexual Activity (HITCH) study is a prospective cohort of 501 college-age women who recently initiated a heterosexual relationship. We tested vaginal samples collected at six clinical visits over 24 months for 36 HPV types. Using rates and Kaplan-Meier analysis, we estimated time-to-event statistics with 95% confidence intervals (CIs) for detection of incident infections and liberal clearance of incident and present-at-baseline infections (separately). We conducted analyses at the woman- and HPV-levels, with HPV types grouped by phylogenetic relatedness.Results By 24 months, we detected incident infections in 40.4%, CI:33.4-48.4 of women. Incident subgenus 1 (43.4, CI:33.6-56.4), 2 (47.1, CI:39.9-55.5) and 3 (46.6, CI:37.7-57.7) infections cleared at similar rates per 1000 infection-months. We observed similar homogeny in HPV-level clearance rates among present-at-baseline infections.Conclusions Our woman-level analyses of infection detection and clearance agreed with similar studies. However, our HPV-level analyses did not clearly indicate that high oncogenic risk subgenus 2 infections take longer to clear than their low oncogenic risk and commensal subgenera 1 and 3 counterparts.Competing Interest StatementA.W.A. received a graduate stipend from the Gerald Bronfman Department of Oncology, McGill University and a presenter’s award from the Experimental Medicine Students’ Society, McGill University. M.E.Z. and E.L.F. hold a patent related to the discovery “DNA methylation markers for early detection of cervical cancer,” registered at the Office of Innovation and Partnerships, McGill University, Montréal, Québec, Canada (October 2018). A provisional utility patent application before the United States Patent and Trademark Office was also filed (November 2018) and a patent cooperation treaty application (PCT/IB2020/050885), filed in February 2020, has been published (no. WO 2020/115728; June 2020). E.L.F. reports grants and personal fees from Merck outside of the submitted work. F.C. reports grants from Réseau FRQS-SIDA during the conduct of the study, and grants to his institution for HPV-related work from Merck Sharp and Dome, Roche Diagnostics and Becton Dickinson outside of the submitted work. All other authors report no potential conflicts.Clinical Protocols https://doi.org/10.2196/11284 Funding StatementThe HITCH cohort study was supported by the Canadian Institutes of Health Research (grant MOP-68893 and team grant CRN-83320 to E.L.F.) and the US National Institutes of Health (grant RO1AI073889 to E.L.F.). A.N.B. is a Canada Research Chair in Sexually Transmitted Infection Prevention and a recipient of a University of Toronto Department of Family and Community Medicine Non-Clinician Scientist award. Supplementary and unconditional funding support was provided by Merck-Frosst Canada and Merck & Co.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All subjects provided written informed consent for study participation and use of their biological specimens in future studies. HITCH complies with all national/international regulations regarding research with human data and materials, including the Declaration of Helsinki. The study was conducted per the principles and articles stipulated by the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. Ethical approval was obtained from the institutional review boards at McGill University, Concordia University, and the Centre Hospitalier de l'Université de Montréal. Ethics renewal approval is requested annually from McGill University (study number A09-M77-04A).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesHITCH participant consent forms specified that data would be published in aggregate form and that individual-level data would only be available to study investigators. To access individual-level data, please contact Eduardo Franco at eduardo.franco{at}mcgill.ca. Analytical codes and a data dictionary are available on the McGill University Dataverse. https://doi.org/10.5683/SP3/GVR332